 |
 |
 |
| |
Mikael Ørum,
Partner |
 |
 |
| |
Peter
Damsbo, MD,
Partner |
 |
 |
| |
Robert L. Buchanan , PhD,
Attorney at Law, Partner |
|
Martin Austin,
Partner
|
 |
 |
| |
Dede Willis, BSc, MBA,
Partner |
 |
 |
| |
Christina Wagner, PhD, Partner |
 |
 |
| |
Mirko
Stange, PhD,
Partner |
 |
 |
| |
Madeline
Yap, PhD,
Partner |
 |
 |
| |
Konstantinos Alevizopoulos, PhD, Partner |
 |
 |
| |
Spencer Ma MBA, FCPA, ACIS ,
Partner |
 |
 |
| |
Bengt Westrin, PhD, Assoc. Professor,
Partner |
 |
 |
| |
Pieter
Telleman, PhD, MBA,
Senior Advisor |
 |
 |
| |
Lars Hedbys,
M Sc, PhD,
Senior Advisor |
 |
 |
|
 |
| |
| |
|
|
Our Team
Peter
Damsbo, MD |
Partner
Peter Damsbo, MD, joined Ventac Partners as Partner in
June 2009. He has more than 25 years of experience from life science
industry and science, including several years in the United States
heading up clinical development of diabetes products for Novo Nordisk.
Key positions prior to joining Ventac Partners include Chief Medical
Officer at Zealand Pharma, Vice President Clinical Drug Development
at Novo Nordisk Headquarter, Medical Director Diabetes at Novo Nordisk
USA, and Research Fellow at the Steno Diabetes Center.
During his industry career, Peter Damsbo has carried 3 medical
projects from preclinical phase through to worldwide registration,
and conducted numerous drug concept evaluations as well as been involved
in drug licensing deals and due diligence processes.
Peter Damsbo has an extensive experience in interacting with the
health authorities in a number of countries, including most notably
FDA and EMEA.
Peter Damsbo medical expertise spans over several therapeutic areas,
including diabetes, obesity, and metabolic diseases and medical devices.
He is associated consultant to US-based KINEXUM and Danish-based
KLIFO's Drug Development Counselling groups.
Peter Damsbo received his MD from University of Copenhagen. |
|

Peter Damsbo, MD
Partner |
|
|